Continental Advisors LLC grew its holdings in Diplomat Pharmacy, Inc. (NYSE:DPLO) by 30.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,800 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Continental Advisors LLC owned about 0.06% of Diplomat Pharmacy worth $886,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Frontier Capital Management Co. LLC lifted its holdings in shares of Diplomat Pharmacy by 4.1% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 5,677,230 shares of the company’s stock valued at $84,023,000 after buying an additional 221,769 shares during the period. Janus Henderson Group PLC acquired a new position in Diplomat Pharmacy during the second quarter worth $67,476,000. Vanguard Group Inc. raised its holdings in Diplomat Pharmacy by 5.4% during the second quarter. Vanguard Group Inc. now owns 4,077,145 shares of the company’s stock worth $60,342,000 after purchasing an additional 210,334 shares during the last quarter. Davis Selected Advisers raised its holdings in Diplomat Pharmacy by 4.4% during the second quarter. Davis Selected Advisers now owns 1,703,992 shares of the company’s stock worth $25,219,000 after purchasing an additional 71,846 shares during the last quarter. Finally, Cortina Asset Management LLC raised its holdings in Diplomat Pharmacy by 538.8% during the third quarter. Cortina Asset Management LLC now owns 1,616,792 shares of the company’s stock worth $33,484,000 after purchasing an additional 1,363,696 shares during the last quarter. 72.48% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently issued reports on DPLO. Leerink Swann raised Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 price objective for the company in a report on Monday. Deutsche Bank began coverage on Diplomat Pharmacy in a report on Monday, December 4th. They set a “buy” rating and a $22.00 price objective for the company. Robert W. Baird cut Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $18.00 in a report on Thursday, November 16th. BidaskClub cut Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Finally, Needham & Company LLC lifted their price objective on Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $20.72.
Diplomat Pharmacy, Inc. (NYSE:DPLO) opened at $18.75 on Monday. The company has a current ratio of 1.34, a quick ratio of 0.82 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1,290.00, a price-to-earnings ratio of 24.35, a price-to-earnings-growth ratio of 3.38 and a beta of 0.61. Diplomat Pharmacy, Inc. has a 1 year low of $12.25 and a 1 year high of $21.99.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.10. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. Diplomat Pharmacy’s revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.21 earnings per share. sell-side analysts forecast that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current fiscal year.
In other Diplomat Pharmacy news, CFO Atul Kavthekar acquired 2,000 shares of the stock in a transaction dated Monday, November 20th. The stock was acquired at an average price of $15.00 per share, with a total value of $30,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares in the company, valued at $30,000. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Joel Saban acquired 10,000 shares of the stock in a transaction dated Monday, November 20th. The stock was acquired at an average cost of $15.24 per share, with a total value of $152,400.00. Following the transaction, the president now owns 12,000 shares of the company’s stock, valued at $182,880. The disclosure for this purchase can be found here. Insiders have acquired 15,000 shares of company stock valued at $228,780 in the last three months. 30.20% of the stock is currently owned by company insiders.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.